Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis

Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis

More than 10 multiple sclerosis-modifying drugs (MSMDs) are widely used now. Novel MSMDs should be investigated in strict accordance with the evidence-based medicine principles governing clinical trials (of both original drugs and their analogues) that prove the high efficiency, safety, and tolerabi...

Full description

Bibliographic Details
Main Authors: A. N. Boyko, N. N. Spirin, Ya. V. Vlasov, M. N. Zakharova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-12-01
Series:Неврология, нейропсихиатрия, психосоматика
Subjects:
multiple sclerosis
treatment
multiple sclerosis-modifying drugs
clinical trials
Online Access:https://nnp.ima-press.net/nnp/article/view/1229

Similar Items

Similar Items